Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2011 4
2012 4
2013 3
2014 1
2015 2
2016 2
2022 3
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Results by year

Filters applied: . Clear all
Page 1
Metabolic Regulation of Gene Expression by Histone Lysine β-Hydroxybutyrylation.
Xie Z, Zhang D, Chung D, Tang Z, Huang H, Dai L, Qi S, Li J, Colak G, Chen Y, Xia C, Peng C, Ruan H, Kirkey M, Wang D, Jensen LM, Kwon OK, Lee S, Pletcher SD, Tan M, Lombard DB, White KP, Zhao H, Li J, Roeder RG, Yang X, Zhao Y. Xie Z, et al. Among authors: colak g. Mol Cell. 2016 Apr 21;62(2):194-206. doi: 10.1016/j.molcel.2016.03.036. Mol Cell. 2016. PMID: 27105115 Free PMC article.
Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
Harrison CN, Gupta VK, Gerds AT, Rampal R, Verstovsek S, Talpaz M, Kiladjian JJ, Mesa R, Kuykendall AT, Vannucchi AM, Palandri F, Grosicki S, Devos T, Jourdan E, Wondergem MJ, Al-Ali HK, Buxhofer-Ausch V, Alvarez-Larrán A, Patriarca A, Kremyanskaya M, Mead AJ, Akhani S, Sheikine Y, Colak G, Mascarenhas J. Harrison CN, et al. Among authors: colak g. Future Oncol. 2022 Sep;18(27):2987-2997. doi: 10.2217/fon-2022-0484. Epub 2022 Aug 11. Future Oncol. 2022. PMID: 35950489 Free article.
MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis.
Mascarenhas J, Kremyanskaya M, Patriarca A, Palandri F, Devos T, Passamonti F, Rampal RK, Mead AJ, Hobbs G, Scandura JM, Talpaz M, Granacher N, Somervaille TCP, Hoffman R, Wondergem MJ, Salama ME, Colak G, Cui J, Kiladjian JJ, Vannucchi AM, Verstovsek S, Curto-García N, Harrison C, Gupta V. Mascarenhas J, et al. Among authors: colak g. J Clin Oncol. 2023 Nov 10;41(32):4993-5004. doi: 10.1200/JCO.22.01972. Epub 2023 Mar 7. J Clin Oncol. 2023. PMID: 36881782 Free PMC article. Clinical Trial.
Transglutaminase regulation of cell function.
Eckert RL, Kaartinen MT, Nurminskaya M, Belkin AM, Colak G, Johnson GV, Mehta K. Eckert RL, et al. Among authors: colak g. Physiol Rev. 2014 Apr;94(2):383-417. doi: 10.1152/physrev.00019.2013. Physiol Rev. 2014. PMID: 24692352 Free PMC article. Review.
A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma.
Blum KA, Supko JG, Maris MB, Flinn IW, Goy A, Younes A, Bobba S, Senderowicz AM, Efuni S, Rippley R, Colak G, Trojer P, Abramson JS. Blum KA, et al. Among authors: colak g. Cancer Res Commun. 2022 Aug 11;2(8):795-805. doi: 10.1158/2767-9764.CRC-22-0060. eCollection 2022 Aug. Cancer Res Commun. 2022. PMID: 36923307 Free PMC article. Clinical Trial.
Transglutaminase 2: a molecular Swiss army knife.
Gundemir S, Colak G, Tucholski J, Johnson GV. Gundemir S, et al. Among authors: colak g. Biochim Biophys Acta. 2012 Feb;1823(2):406-19. doi: 10.1016/j.bbamcr.2011.09.012. Epub 2011 Oct 10. Biochim Biophys Acta. 2012. PMID: 22015769 Free PMC article. Review.
20 results